HRP20230694T1 - Smanjenje ljudskog respiratornog sincicijskog virusa prema ljestvici genoma deoptimizacijom kodon-para - Google Patents
Smanjenje ljudskog respiratornog sincicijskog virusa prema ljestvici genoma deoptimizacijom kodon-para Download PDFInfo
- Publication number
- HRP20230694T1 HRP20230694T1 HRP20230694TT HRP20230694T HRP20230694T1 HR P20230694 T1 HRP20230694 T1 HR P20230694T1 HR P20230694T T HRP20230694T T HR P20230694TT HR P20230694 T HRP20230694 T HR P20230694T HR P20230694 T1 HRP20230694 T1 HR P20230694T1
- Authority
- HR
- Croatia
- Prior art keywords
- rsv
- protein
- recombinant
- seq
- human subgroup
- Prior art date
Links
- 241000711920 Human orthopneumovirus Species 0.000 title 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims 24
- 239000002773 nucleotide Substances 0.000 claims 17
- 125000003729 nucleotide group Chemical group 0.000 claims 17
- 108091033319 polynucleotide Proteins 0.000 claims 15
- 239000002157 polynucleotide Substances 0.000 claims 15
- 102000040430 polynucleotide Human genes 0.000 claims 15
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims 8
- 235000001014 amino acid Nutrition 0.000 claims 4
- 229940024606 amino acid Drugs 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 108020004705 Codon Proteins 0.000 claims 3
- 101710141454 Nucleoprotein Proteins 0.000 claims 3
- 101710177166 Phosphoprotein Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 241000282552 Chlorocebus aethiops Species 0.000 claims 2
- 101150039699 M2-1 gene Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 102100034574 P protein Human genes 0.000 claims 1
- 101710181008 P protein Proteins 0.000 claims 1
- 101710183921 Protein M2-1 Proteins 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000007923 nasal drop Substances 0.000 claims 1
- 229940100662 nasal drops Drugs 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 102200017393 rs104894299 Human genes 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00061—Methods of inactivation or attenuation
- C12N2760/00062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18561—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18561—Methods of inactivation or attenuation
- C12N2760/18562—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (15)
1. Rekombinantni polinukleotid koji kodira smanjeni respiratorni sincicijski virus (RSV) ljudske podskupine A,
pri čemu rekombinantni polinukleotid sadrži nukleotidnu sekvencu koja kodira protein RSV L,
pri čemu protein RSV L ima aminokiselinsku sekvencu koja se razlikuje za najviše jedan aminokiselinski ostatak od aminokiselinske sekvence kodirane nukleotidima 8387 do 14884 SEQ ID NO: 1,
pri čemu je nukleotidna sekvenca koja kodira protein RSV L od 75% do 85% identična nukleotidima 8387 do 14884 SEQ ID NO: 1,
pri čemu je nukleotidna sekvenca koja kodira protein RSV L deoptimizirana za kodon-par,
pri čemu je odstupanje kodon-para nukleotidne sekvence koja kodira protein RSV L smanjeno za najmanje 0.2 u odnosu na nukleotide 8387 do 14884 SEQ ID NO: 1,
pri čemu se smanjena ljudska podskupina A RSV replicira najmanje 100 puta niže od divljeg tipa RSV u donjem respiratornom traktu afričkih zelenih majmuna, i
pri čemu smanjena ljudska podskupina A RSV inducira neutralizirajuća antitijela kod afričkih zelenih majmuna.
2. Rekombinantni polinukleotid prema bilo kojem od prethodnih zahtjeva, naznačen time što je nukleotidna sekvenca koja kodira protein RSV L 79% identična nukleotidima 8387 do 14884 SEQ ID NO: 1.
3. Rekombinantni polinukleotid prema bilo kojem od prethodnih zahtjeva, naznačen time što nukleotidna sekvenca koja kodira protein RSV L sadrži nukleotide 8387 do 14884 SEQ ID NO: 5.
4. Rekombinantni polinukleotid prema bilo kojem od prethodnih zahtjeva, naznačen time što je aminokiselinska sekvenca protein RSV L kodirana nukleotidima 8387 do 14884 SEQ ID NO: 1.
5. Rekombinantni polinukleotid prema bilo kojem od prethodnih zahtjeva, naznačen time što je nukleotidna sekvenca deoptimizirana kodon-parom za najmanje jedan dodatni protein RSV odabran između: NS1, NS2, N, P, M, SH, G, i F.
6. Rekombinantni polinukleotid prema bilo kojem od prethodnih zahtjeva, naznačen time što je nukleotidna sekvenca SEQ ID NO: 4 ili SEQ ID NO: 5.
7. Rekombinantni polinukleotid prema bilo kojem od prethodnih zahtjeva, koji nadalje sadrži promjenu nukleotida u jednom ili više od sljedećeg:
a. promjena u kodonu koji kodira aminokiselinu 136 proteina N,
b. promjena u kodonu koji kodira aminokiselinu 114 proteina P, ili
c. promjena u kodonu koji kodira aminokiselinu 88 proteina M2-1.
8. Rekombinantni polinukleotid prema zahtjevu 7, naznačen time što bilo koja od promjena nukleotida uzrokuje aminokiselinu koja nije:
a. lizin koji će biti kodiran na položaju 136 proteina N,
b. glutaminska kiselina koja se kodira na položaju 114 proteina P, ili
c. asparagin koji se kodira na poziciji 88 proteina M2-1.
9. Rekombinantni smanjeni genom RSV ljudske podskupine A koji sadrži rekombinantni polinukleotid prema bilo kojem od prethodnih zahtjeva; ili odgovarajući antigenom koji sadrži polinukleotid komplementaran rekombinantnom polinukleotidu.
10. Rekombinantni smanjeni genom RSV ljudske podskupine A koji sadrži rekombinantni polinukleotid prema bilo kojem od prethodnih zahtjeva, pri čemu je nukleotidna sekvenca SEQ ID NO: 4 izborno modificirana da kodira jednu ili više sljedećih mutacija: K136R u proteinu N, E114V u proteinu P i N88K u proteinu M2-1, ili SEQ ID NO: 5; ili odgovarajući antigenom koji sadrži polinukleotid komplementaran rekombinantnom polinukleotidu.
11. Rekombinantna smanjena ljudska podskupina A RSV sadrži rekombinantni genom RSV ljudske podskupine A prema zahtjevu 9 ili zahtjevu 10.
12. Postupak proizvodnje rekombinantne smanjene ljudske podskupine A RSV, koja se sastoji od ekspresije genoma RSV rekombinantne smanjene ljudske podskupine A prema zahtjevu 9 ili zahtjevu 10 u stanici.
13. Rekombinantna smanjena ljudska podskupina A RSV prema zahtjevu 11 za uporabu u terapiji.
14. Rekombinantna smanjena ljudska podskupina A RSV za uporabu prema zahtjevu 13, naznačena time što se RSV primjenjuje putem injekcije, aerosolne primjene, nazalnog spreja, nazalnih kapljica, oralne inokulacije, ili lokalne primjene.
15. Pripravak cjepiva koji sadrži rekombinantnu smanjenu ljudsku podskupinu A RSV prema zahtjevu 11.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361762768P | 2013-02-08 | 2013-02-08 | |
| US201361794155P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/015274 WO2014124238A1 (en) | 2013-02-08 | 2014-02-07 | Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization |
| EP14706207.9A EP2954049B1 (en) | 2013-02-08 | 2014-02-07 | Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230694T1 true HRP20230694T1 (hr) | 2023-10-13 |
Family
ID=50156946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230694TT HRP20230694T1 (hr) | 2013-02-08 | 2014-02-07 | Smanjenje ljudskog respiratornog sincicijskog virusa prema ljestvici genoma deoptimizacijom kodon-para |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9957486B2 (hr) |
| EP (2) | EP4190895A1 (hr) |
| AU (3) | AU2014214763B2 (hr) |
| CA (1) | CA2900713A1 (hr) |
| ES (1) | ES2952387T3 (hr) |
| HR (1) | HRP20230694T1 (hr) |
| PL (1) | PL2954049T3 (hr) |
| WO (1) | WO2014124238A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2954049T3 (pl) | 2013-02-08 | 2023-10-16 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Atenuacja ludzkiego syncytialnego wirusa oddechowego przez deoptymalizację par kodonów w skali genomu |
| WO2014152534A1 (en) * | 2013-03-14 | 2014-09-25 | Emory University | Recombinant rsv with silent mutations, vaccines, and methods related thereto |
| WO2014145290A1 (en) | 2013-03-15 | 2014-09-18 | The Research Foundation For The State University Of New York | Attenuated influenza viruses and vaccines |
| WO2015183895A1 (en) | 2014-05-27 | 2015-12-03 | University Of Rochester | Novel arenavirus vaccine |
| JP7311872B2 (ja) | 2015-10-29 | 2023-07-20 | エモリー ユニバーシティー | キメラｒｓｖ、免疫原性組成物、及び使用方法 |
| JP7198759B2 (ja) * | 2016-09-23 | 2023-01-04 | ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズ | 弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補 |
| CN116348594A (zh) * | 2020-05-13 | 2023-06-27 | 美国卫生和人力服务部 | 携带一个或多个p基因突变的rsv疫苗 |
| AU2021285997A1 (en) * | 2020-06-05 | 2023-01-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Live attenuated respiratory syncytial virus |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100658491B1 (ko) | 1996-07-15 | 2006-12-18 | 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 | 클론닝된 뉴클레오타이드 서열로부터 약독화된 호흡기 세포 융합 바이러스 백신의 생산 |
| AU7797798A (en) | 1997-05-23 | 1998-12-11 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences |
| EP1690940A1 (en) * | 1999-04-13 | 2006-08-16 | The Government of the United States of America as Represented by The Department of Health and Human Services | Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences |
| US20040161846A1 (en) * | 2000-11-22 | 2004-08-19 | Mason Anthony John | Method of expression and agents identified thereby |
| US7297786B2 (en) * | 2004-07-09 | 2007-11-20 | University Of Iowa Research Foundation | RNA interference in respiratory epitheial cells |
| CA2587084C (en) | 2004-10-08 | 2019-07-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Modulation of replicative fitness by using less frequently used synonym ous codons |
| KR101621100B1 (ko) * | 2007-03-30 | 2016-05-13 | 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 | 백신에 유용한 약독화 바이러스 |
| AU2009311287C1 (en) | 2008-11-05 | 2015-02-19 | Merck Sharp & Dohme Corp. | Live, attentuated respiratory syncytial virus |
| US10227569B2 (en) | 2011-04-12 | 2019-03-12 | Emory University | Respiratory syncytial virus expression vectors |
| PL2954049T3 (pl) * | 2013-02-08 | 2023-10-16 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Atenuacja ludzkiego syncytialnego wirusa oddechowego przez deoptymalizację par kodonów w skali genomu |
| JP7198759B2 (ja) | 2016-09-23 | 2023-01-04 | ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズ | 弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補 |
-
2014
- 2014-02-07 PL PL14706207.9T patent/PL2954049T3/pl unknown
- 2014-02-07 EP EP22201434.2A patent/EP4190895A1/en active Pending
- 2014-02-07 CA CA2900713A patent/CA2900713A1/en active Pending
- 2014-02-07 HR HRP20230694TT patent/HRP20230694T1/hr unknown
- 2014-02-07 US US14/766,620 patent/US9957486B2/en active Active
- 2014-02-07 AU AU2014214763A patent/AU2014214763B2/en active Active
- 2014-02-07 WO PCT/US2014/015274 patent/WO2014124238A1/en active Application Filing
- 2014-02-07 EP EP14706207.9A patent/EP2954049B1/en active Active
- 2014-02-07 ES ES14706207T patent/ES2952387T3/es active Active
-
2018
- 2018-03-16 US US15/924,012 patent/US11371024B2/en active Active
-
2020
- 2020-05-26 AU AU2020203460A patent/AU2020203460B2/en active Active
-
2022
- 2022-06-02 US US17/831,259 patent/US20220325252A1/en active Pending
- 2022-12-01 AU AU2022279509A patent/AU2022279509A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20150368622A1 (en) | 2015-12-24 |
| AU2014214763B2 (en) | 2020-02-27 |
| US20220325252A1 (en) | 2022-10-13 |
| AU2020203460B2 (en) | 2022-09-08 |
| US20180208906A1 (en) | 2018-07-26 |
| WO2014124238A1 (en) | 2014-08-14 |
| US9957486B2 (en) | 2018-05-01 |
| AU2020203460A1 (en) | 2020-06-18 |
| WO2014124238A8 (en) | 2015-09-24 |
| CA2900713A1 (en) | 2014-08-14 |
| PL2954049T3 (pl) | 2023-10-16 |
| AU2014214763A1 (en) | 2015-08-27 |
| EP2954049B1 (en) | 2023-05-17 |
| EP2954049A1 (en) | 2015-12-16 |
| AU2022279509A1 (en) | 2023-02-02 |
| ES2952387T3 (es) | 2023-10-31 |
| EP4190895A1 (en) | 2023-06-07 |
| US11371024B2 (en) | 2022-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230694T1 (hr) | Smanjenje ljudskog respiratornog sincicijskog virusa prema ljestvici genoma deoptimizacijom kodon-para | |
| HRP20200871T1 (hr) | Izmjenjeni rsv f proteini i postupci njihove uporabe | |
| HRP20190928T1 (hr) | Modificirani fenilalanin amonijak-liazni polipeptidi | |
| Rajao et al. | Pathogenesis and vaccination of influenza A virus in swine | |
| Centers for Disease Control and Prevention (CDC | Rotavirus surveillance---worldwide, 2009 | |
| HRP20171194T1 (hr) | Trovalentni konstrukti nanotijela protiv ljudskog respiratornog sincicijskog virusa (hrsv) za prevenciju i/ili liječenje infekcija dišnih puteva | |
| HRP20161608T1 (hr) | Modificirani tuberkulozni antigeni | |
| GEP20217260B (en) | Antibody neutralizing human respiratory syncytial virus | |
| NZ627888A (en) | Materials and methods for respiratory disease control in canines | |
| HRP20191291T1 (hr) | Imunogeni pripravak | |
| UA101597C2 (uk) | Псевдоінфекційний флавівірус та його використання | |
| WO2013151670A3 (en) | Modified polynucleotides for the production of nuclear proteins | |
| JP2015514132A5 (hr) | ||
| NO20072882L (no) | Defekte influensaviruspartikler. | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| JP2019534709A5 (hr) | ||
| JP2017502662A5 (hr) | ||
| WO2014150822A3 (en) | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use | |
| US20230414745A1 (en) | Influenza virus encoding a truncated ns1 protein and a sars-cov receptor binding domain | |
| JP2014504297A5 (hr) | ||
| HRP20191864T1 (hr) | Imunogeni pripravci protiv bakterije clostridium difficile | |
| Halpin et al. | Recent progress in henipavirus research | |
| Mi et al. | Kappa-RBD produced by glycoengineered Pichia pastoris elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants | |
| NZ712713A (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
| CN103316357B (zh) | 携带rsv基因的重组流感病毒嵌合疫苗及其制备方法 |